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The potential usefulness of orthotopic liver 
transplantation (OLTx) in the treatment of end-
stage liver diseases was recognized in the 1950's, 
and the first clinical attempt was carried out at 
the University of Colorado in Denver, on March 
1, 1963125. It was unsuccessful: the three year old 
patient, affected by extrahepatic biliary atresia, 
exsanguinated on the operating table. Among 
the next eight patients, transplanted in Denver (6 
patients 112) , Boston (1 patients1), and Paris (1 
patient23), the longest survival was 23 days 112 . 
The first long-term survivor was a child trans-
planted for hepatoma on July 23, 1967, who died 
of carcinomatosis 400 days later118. The late 
1960's and early 1970's saw very slow progress in 
this field, with patients suffering from frequent 
and disabling complications, and an overall one-
year patient survival of only 35%122. By then, the 
technical steps of the standard procedure had 
already been precisely described, and the surgi-
cal technique that is currently used at the 
Pittsburgh Transplantation Institute (p. 1779), is 
essentially the one developed at the University 
of Colorado in the 1960'sl11, 125. On the other 
hand, the indications for OLTx were much more 
limited in those early days, and the list of the dis-
eases being treated with this procedure has 
grown significantly in the past 30 years. For 
example, postnecrotic cirrhosis of any etiology 
is today the most common indication for OLTx 
in most liver transplant centers, while only one 
patient in the original Denver series had post-
necrotic cirrhosisllO• The reason for the paucity 
of cirrhotic patients (other than biliary atresia) 
in the early trials was that, while the fate of the 
patient with a liver malignancy or extrahepatic 
biliary atresia was easy to predict, the prognosis 
of a stable patient with cirrhosis could not be 
predicted as readily. 
Therefore, given the uncertamty surrounding 
the operation, most candidates were first consid-
ered only when they were already moribund, 
usually as a consequence of recent or ongoing 
variceal hemorrhage, and most died while await-
ing for a suitable donor.· It was the routine 
achievement of long term survival (the longest 
surviving recipient was transplanted 26 years 
ago), several immunological advances1, 11, 13, 14, 
68, 115, 116, 117, 123, 124, 127, 135, and the progress in 
donor surgery70, 120, 126, and organ preserva-
tion50,51, 136, that led to an expansion of indica-
tions for OLTx. As a consequence, diseases that 
were not considered before are now successful-
ly treated with OLTx, and the procedure could 
be used for virtually any patient suffering from a 
lethal hepatic disease. 
In 1982 it was estimated that the annual need 
for OLTx was 15 per million populationl23, but is 
probably now higher, as the advances of the past 
decade allow us to treat patients that not long 
ago would have been considered not transplant-
able. In fact, depending on the criteria used to 
determine what are appropriate indications, we 
can estimate that between 40,000 and 50,000 
OLTx's may be needed in the United States 
every year, with a similar number in Europe116. 
But, while in the past, the appropriateness of the 
decision to proceed with transplantation was 
judged largely on the basis of technical and med-
ical factors related to the recipient, nowadays it 
is the supply of organs that increasingly shapes 
these decisions. If substantial growth is to occur, 
there will have to be a re-evaluation of the poli-
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des that surround organ donation39,69,g9. In this 
('hapter, we will outline the diseases that are 
p!'esently considered as indications for OLTx , 
mid we will report the results obtained in 1,501 
consecutive patients who underwent OLTx at the 
?ittsburgh Transplantation Institute between 
January 1, 1990 and December 31, 1993. 
HIDICATIONS FOR LIVER 
C{'RANSPLANTATION 
The indications for OLTx were mostly defined at 
the National Institute of Health (NIH) Consensus 
Development Conference on Liver Trans-
plantation, held in June 198383• There are four 
main groups: parenchymal liver diseases, choles-
tatic liver diseases, congenital errors of metab-
olism, and hepatic tumors. (Table 7.49). 
PARENCHYMAL LIVER DISEASE 
There are many causes of parenchymal liver irtiu-
ry that may lead to acute or chronic liver failure 
that grossly impairs the quality of life or poses an 
acute obstacle to survival. The choice of OLTx is 
predicated on the knowledge that other thera-
pies are ineffective in decreasing morbidity, or in 
simply rescuing the patient's life. 
Postnecrotic Cirrhosis 
The most common indication for OLTx in adults 
is postnecrotic cirrhosis. The main etiology is 
chronic viral hepatitis, which may result from 
hepatitis B virus (HBV), with or without co-infec-
tion with hepatitis delta virus (HDV), from hepa-
titis C virus (HCV), or from other, not yet charac-
terized viral agents. The other large group is 
formed by patients with cryptogenic disease, 
which is a heterogenous group in whom no 
defined etiology can be identified. There are no 
special features of this subset with regard to 
OLTx candidacy. 
It should be noted that the true incidence of hep-
atitis C (and the risk for reinfection) in the popu-
lation presented below is not known, because 
the test for the antibody against this agent was 
not routinely available until May, 1990. In many 
areas of the world, infection with HBV is endem-
ic, and the most common cause of advanced 
liver disease and hepatocellular carcinoma 
Recurrence of infection after transplantation 
is high in HBsAg+ patients. In a previous report, 
the outcome of 59 patients with prior HBV infec-
tion was compared to that of 38 patients who 
had immunity to HVB. The mortality, rate of graft 
loss, and need for retransplantation were signifi-
cantly higher in the group with prior HBV infec-
tionl34. In the same study, an active immuniza-
tion with HBsAg vaccine and passive administra-
tion with hepatitis B immune globulin led to 
clearance of HBsAg in 6 of 22 patients. Also, in 
this series none of the patients with HBeAg sero-
converted. Efforts to reduce the incidence and 
severity of reinfection, with the use of a-interfer-
on and active and passive immunization, have 
been done in many institutions. A large series of 
patients were analyzed in a retrospective multi-
center study performed in Europe. Three hun-
dred and seventy-two HBsAg positive patients 
underwent OLTx at 17 centers106. Patients were 
stratified as to the serologic markers for hepa-
titis B, acute fulminant versus chronic, coexis-
tent HDV infection, and the length of hepatitis B 
immune globulin treatment. The mean three year 
actuarial risk of recurrence of HBV was 50%. 
Eighty-three percent of HBV DNA positive hav-
ing recurrence; 66% of the HBeAg positive, DNA 
negative recurring; and 58% of HBV DNA 
negative, HBeAg negative recurring. Patients 
who have co-existent HDV infection in chronic 
phase, had a 32% incidence of recurrence, and 
those with fulminant hepatic failure related to 
hepatitis B virus had a 17% recurrence rate. 
Recurrence as related to hepatitis B immune 
globulin therapy revealed that no therapy was 
associated with 75% rate of recurrence, while 
those with short term therapy (less than 6 
months of hepatitis B immune globulin) had a 
74% recurrence rate. Those with more than 6 
months of hepatitis B immune globulin had a 
35% recurrence rate. At the Pittsburgh 
Transplantation Institute, 69 patients who under-
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Table 7.49 - Native liver disease in 215 pediatric 
and 1,286 adult recipients who underwent 
orthotopic liver transplants at the Pittsburgh 
Transplantation Institute between January 1, 
1990 and December 31,1993 
Disease 
Parenchymal 
Postnecrotic cirrhosis 
Alcoholic cirrhosis 
AutoirnmWle hepatitis 
Fulminant and subfulminant 
hepatic failure 
Budd-Chiari syndrome 
Cystic fibrosis 
Congenital hepatic fibrosis 
Neonatal hepatitis 
Cholestatic 
Primary biliary cirrhosis 
Biliary atresia 
Sclerosing cholangitis 
Secondary biliary cirrhosis 
Familial cholestasis 
Congenital errors of 
metabolism 
Tumors 
Benign 
Primary malignant 
Metastatic 
Miscellaneous 
TOTAL 
43 patients also had HCC 
Number of cases 
487* 
293** 
53*** 
42+ 
15++ 
10 
9 
6 
116; 
103 
99H 
21tH 
80 
5800 
2 
107 
13 
59000 
1,501 
** 13 patients also had HCC and 1 patient also had 
cholangiocarcinoma 
*** 1 patient also had HCC 
1 patient also had HCC 
++ 1 patient also had HCC 
6 patients also had HCC 
+ 
:j: 
:j::j: 1 patient also had HCC, 1 patient also had 
gallbladder cancer, and 1 patient also had metastatic 
cancer 
H:j: 2 patients also had HCC 
1 patient also had HCC 
00 2 patients also had HCC 
000 2 patients also had HCC 
went OLTx between 1988 and 1992, were ana-
lyzed according to the HBeAg status, and t11(' 
length of hepatitis B immune globulin treatment. 
The mean two year recurrence rate for thi(: 
group of patients was 67%. Those who receiv€cl 
long tenn hepatitis B immune globulin treatment 
had a recurrence rate of 60%, while those who 
had a treatment lasting for less than 6 month~~ 
had a recurrence rate of 75%, and a small subse1 
that did not receive any hepatitis B immune glob-
ulin treatment (9 patients) had a recurrence rate 
of 100%. Patients that were HBeAg positive had a 
three year recurrence rate of 80%, while those 
who were HBeAg negative had a three year 
recurrence rate of 46%. 
Despite the high rate of recurrence, we do not 
believe that there should be an across the board 
ban on liver patients with HBV infection. Rather 
than simply de clearing defeat, we should study 
the effects of new and promising agents, such as 
iamivudine, as we continue to strive to develop 
new strategies for the prevention or treatment of 
recurrent hepatitis B. 
Alcoholic Cirrhosis 
About 100;6 of the adult population of the United 
States have a history of alcohol abuse96, and 
alcoholic liver disease is the most common 
cause of chronic liver disease in western society. 
Alcohol-induced liver injury is a prime example 
of a disease in which OLTx might have been pre-
cluded, or strongly discouraged, 10 years ago. 
With a multidisciplinary approach to substance 
abuse, properly selected cases of alcoholic cir-
rhosis have outcomes after transplantation that 
are comparable to those of other non-malignant 
diseases129. At our institution, the acceptance of 
these patients as candidates for transplantation 
usually requires a previous successful rehabilita-
tion, with documented abstinence. However, we 
do not believe that patients should be allowed to 
die if they are too sick to meet an arbitrary peri-
od of sobriety, and in circumstances such as 
these we evaluate the patient's familial and social 
involvement before making a determination. 
This process requires an active involvement on 
the part of social workers, psychologists, psychi-
atrists and other professionals. 
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Autoimmune Hepatitis 
Autoimmune hepatitis most commonly presents 
in women between the ages of 15 and 25, with a 
second peak in post-menopause. Corticosteroid 
therapy is effective in prolonging life (5-year sur-
vival of 85% in treated patients vs. 400;6 in the con-
trol group57). However, when liver function has 
been seriously compromised, and quality of life 
is significantly affected, OLTx represents the 
only therapeutic option. Attention should be paid 
to the possibility that the patient may harbor a 
resistant opportunistic infection (particularly 
fungal) related to the prolonged immunosuppres-
sive treatment. If present, these infections obvi-
ously need to be treated prior to accepting the 
patient as a transplant candidate. 
We should mention that, more recently, a new 
approach was tried for this group of patients, 
with encouraging preliminary results. A group of 
21 patients with biopsy-proven autoimmune 
chronic active hepatitis were given the new 
immunosuppressive drug tacrolimus (formerly 
FK506)127. After three months of therapy, the 
serum ALT level was reduced by 80% and the 
AST by 70%144. These data suggest that tacroli-
mus should be compared to prednisolone in a 
randomized trial, to identify the best available 
medical treatment. If these preliminary results 
are confirmed, it is conceivable that the natural 
history of autoimmune hepatitis will be changed 
such that liver failure might be averted. 
Fulminant Hepatic Failure 
A diagnosis of fulminant hepatic failure can be 
made when jaundice and hepatic encephalopa-
thy develop within 8 weeks of onset of the illness 
in a patient who was previously healthy7, 137. 
Some patients may develop encephalopathy after 
8 weeks from the onset of symptoms, in the 
absence of pre-existing liver disease. This subset 
of patients has been described as "late onset 
hepatic failure" by the English literature85, or 
"sub fulminant hepatic failure" by the French 
literature7. The prognosis is very grim in both 
conditions, with a Jllortality greater than 70% 
when the patient pr6'fesses to grade 4 encepha-
lopathyB7, 93,100, 138, 147. The leading causes are 
hepatitis viruses and drug hepatotoxicity caused 
by a variety of agents. The prognosis changes in 
relation to the etiology, with acetaminophen-
induced liver injury having the best rate of recov-
ery with medical treatment alone (approximately 
500;6 survival in series of 32 cases87), and fulmi-
nant non-A non-B hepatitis and other drug hepat-
otoxicity (Le. halothane) having the worst out-
come. 
Before 1982, results with OLTx were not good 
enough to justify advocating it for this patient 
population123, since recovery without liver 
replacement occurred in 5 to 200;6 of cases7, 137. 
However, the results with transplantation have 
steadily improved in the past decade, and in a 
recently reported series of more than 600 OLTx 
for fulminant hepatic failure, the one year survi-
val rate was 630/;4. In light of this progress, OLTx 
has become widely accepted as therapy for this 
indication9, 47, 87,102. 
The decision to replace an acutely failing liver 
is a most difficult one, and must often be made 
within a few hours. A systematic assessment can 
help establish whether the patient belongs to the 
subset that has a good chance of recovery, or 
identify those who have a high probability of 
dying without transplantation18, 88As mentioned 
before, the etiology is an important prognostic 
determinant85, with fulminant hepatitis Band 
non-A non-B (most of which, later on, have 
shown to be cases of hepatitis C) having a much 
worse prognosis than fulminant hepatitis A. 
Other features that predict imminent death 
include relentless progression to grade 3 or 4 
coma, severe coagulopathy, rapid liver necrosis, 
acidosis, renal failure and hemodynamic instabil-
ity. The perioperative mortality is often related to 
brain-stem herniation during or just after the 
OLTx, sometimes despite the continuous moni-
toring of intracranial pressure. In general, refer-
ral to a liver transplant program should be done 
as early as possible, because it is the only treat-
ment modality for a significant percentage of 
patients with fu1rninant hepatic failure24. 
Budd-Chiari Syndrome 
The Budd-Chiari syndrome, caused by an 
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obstruction of the main hepatic veins, can be 
found in association with a wide variety of disor-
ders, such as paroxysmal nocturnal hemoglobi-
nuria, polycythemia vera and other myeloprolif-
erative diseases, tumors of the adrenal glands or 
kidneys, hepatomas, amoebic abscesses, congen-
ital vena cava webs, contraceptives, pregnancy, 
antithrombin III deficiencies and lupus anticoag-
ulants21, 27, 45, 56, 80,91, 101, 142, 143, 149. The number 
of different surgical procedures that have been 
proposed to treat Budd-Chiari has been reported 
to be as high as 233 and the results vary great-
ly12The procedures most commonly used in the 
United States are the side-to-side portocaval and 
mesocaval shunts, when the inferior vena cava 
and portal vein are patent, and the meso atrial 
shunt when the inferior vena cava is stenosed or 
thrombosed and the portal vein is patent. 
Success rates with these procedures range from 
300;6 to 92%, with the majority being in the 60% to 
75% range42. However, when there is progressive 
liver failure, and no concomitant neoplastic dis-
ease, Budd-Chiari syndrome can be successfully 
managed by OLTx. The first liver transplant for 
this disorder was performed by our group on 
November 28, 1974. The patient is still alive and 
well 20 years after the procedure, and has had 
two children. Since that time, a number of 
patients with this condition have been treated 
with liver transplantation in many institutions 15, 
42. Based on our experience, and that of the 
Cambridge group15, it is clear that liver trans-
plantation is indicated for the Budd-Chiari syn-
drome once it has progressed to end-stage liver 
disease. Whether to transplant or shunt those 
patients with intermediate degrees of liver fail-
ure is currently uncertain. An interesting point is 
that the Budd-Chiari syndrome can recur after 
liver transplantation, as it happened to 3 of the 
patients we reported recently, all of whom 
died42. 
Other Parenchymal Diseases 
There are many other hepatic parenchymal dis-
eases for which liver transplantation has been 
successfully performed, including, but not limit-
ed to, cystic fibrosis78, congenital hepatic fibro-
sis, and neonatal hepatitis. Liver transplantation 
once seemed so drastic a measure that it was 
used only as a last resort for "benign" hepatic 
disease 114. Today, on the contrary, allowing a 
patient to deteriorate to the point that life-sup-
port devices are required before considering 
transplantation is unacceptable. 
CHOLESTATIC LIVER DISEASES 
Cholestatic liver diseases are a group of condi-
tions characterized by bile duct injury which 
results in severe impairment of bile excretion 
and hepatocellular dysfunction. These events 
may ultimately lead to cirrhosis. Liver transplan-
tation has provided patients with these disorders 
a chance for near-normal long-term survival. 
Primary Biliary Cirrhosis 
Primary biliary cirrhosis (PBC) , or chronic non-
suppurative destructive cholangitis (p. 220), is a 
disorder that primarily affects middle-aged 
women, with a ratio of women to men of approx-
imately 10: 152. The 5-year survival of patients 
with PBC, not treated with liver transplantation, 
ranges from 300;6 to 700;619, 103. The fact that the 
natural history of PBC is reasonably well charac-
terized has allowed to study the influence of the 
stage of the disease on the outcome after liver 
transplantation74,84. In one such investigation74, 
the survival following liver transplantation was 
markedly better than that predicted (assuming 
no transplantation) using survival analysis25. It is 
clear that in PBC the timing of transplantation is 
critical, and it should be carried out before the 
stage of catastrophic deterioration is reached. 
The quality of life of individuals transplanted for 
PBC has been very good, with ninety percent of 
long-term survivors being fully rehabilitated31. 
We should note here that, while the I-year survi-
val rates after transplantation was 83%, 75% and 
58%, according to the candidate risk category 
(low, medium, and high respectively), the actual 
gain in survival is particularly significant in the 
high-risk candidates74. In fact, if we compare 
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these survival rates with the ones predicted by 
the Mayo prognostic model for PBC25, there is a 
58% gain in survival at I-year in the high-risk can-
didates, 55% in the medium-risk candidates, and 
only 14 % in the low-risk candidates30. These 
data should be kept in mind when establishing 
candidacy and liver transplantation priority for 
this category of patients. 
Biliary Atresia 
Biliary atresia is by far the most common indica-
tion for liver transplantation in children4, 5. The 
diseaSe is already obvious in the neonate, char-
acterized by increasingly severe cholestasis dur-
fig the first 90 days of life and, unless treated, it 
is universally fatal. Children with this anomaly 
are oft-en treated with a portoenterostomy 
(Kasai operation)53 (p. 1727). However, only a 
small subset has been actually cured by this pro-
cedure, and most children die of liver failure that 
continues to progress after surgery. It is estimat-
ed that 75% of the patients suffering from biliary 
atresia will eventually require a liver transplant, 
regardless of any previous surgical treatment96. 
If a Kasai operation is performed, it should be 
done 60 to 90 days after birth to be successful. 
Also, it is important to avoid re-operation after 
an initial portoenterostomy, except to correct 
minor technical faults, or for relief of obstruc-
tions due to biliary stones. In fact, other re-oper-
ations are usually unsuccessful, and might seri-
ously jeopardize a later transplant. Long-term 
survival after liver transplantation is excellent, 
ranging between 80% and 85% in most series, 
with an essentially flat survival curve after the 
first 6 months. The three principal causes of liver 
failure after liver transplantation for biliary atre-
sia are thrombosis of the hepatic artery, primary 
allograft non function, and rejection33, 37. The 
quality of life of the long-term survivors is excel-
lent, and the majority of these children have a 
very satisfactory growth and intellectual devel-
opment141. 
Sclerosing Cholangitis 
Primary sclerosing cholangitis (PSC) (p. 481) is a 
chronic cholestatic liver disease which is 
extremely difficult to define accurately60, 76. It is 
recognized by liver dysTImction and a character-
istic radiological appearance (with multiple 
localized strictures and dilatation, in the absence 
of known causes of sclerosis, such as operative 
trauma, calculus disease or congenital anoma-
lies), which is related to portal tract inflamma-
tion, bile duct proliferation, and periductal fibro-
sis involving small intrahepatic and large extra-
hepatic ducts. The introduction of endoscopic 
retrograde cholangiography in clinical practice 
has resulted in a marked development in the 
understanding of the clinical, radiological, and 
histlogical picture of PSC43. However, despite 
this progress, the etiology is still unknown, and 
no curative medical treatment has been identi-
fied. 
In contrast to PBC, PSC affects mainly men 
(sex ratio 4:1) who are 30 to 50 years old. Until 
recently, patients with PSC often underwent dif-
ferent biliary operations for diagnostic or pallia-
tive purposes (such as surgical exploration of 
the biliary tree, T-tube placement, biliary stenting 
or reconstruction, or both). All these procedures 
failed to achieve long-term benefits 75 and just 
served to promote episodes of cholangitis and 
strong adhesions in the hepatic hilum. Liver 
transplantation offers the only prospect for cure 
and long term survival to patients with PSC in 
the terminal stage of the disease, and all other 
surgical approaches (with the exception of endo-
scopic retrograde cholangiography and percut-
aneous liver biopsy) should be abandoned. 
Recently, the survival of 216 patients trans-
planted for PSC was compared with the predic-
tions made by survival analysis (again, assuming 
no transplantation)2. The model incorporates 
physical findings, biochemical and histopatho-
logic features of PSC, and was developed in a 
study of 426 patients affected by PSC and man-
aged conservatively in five institutions from 
Europe and North America26. The 5-years 
Kaplan-Meier actuarial survival after liver trans-
plantation was 73%, compared to 28% expected 
survival according to the above mentioned 
model. Similarly to what is observed with PBC 
patients30, the most important gain in survival in 
patients with PSC corresponds to the high-risk 
group. If we compare the survival rates with the 
ones predicted by the Mayo prognostic model for 
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PSC26, the gain in I-year survival with liver trans-
plantation is only 7% in the low-risk patients, and 
as high as 400Al in the high-risk group30. Again, 
this information should be seriously considered 
when formulating policies for candidate selec-
tion and transplantation priority criteria. 
Other Cholestatic Diseases 
Liver transplantation is indicated as surgical 
treatment of a number of other cholestatic dis-
eases. Secondary biliary cirrhosis, Caroli's dis-
ease (p. 521), familial cholestasis, and Alagille's 
syndrome (p. 515) are the most important diseas-
es in this group. 
In a series of 10 patients transplanted for 
Caroli's disease at the Pittsburgh Transplantation 
Institute, 7 patients were alive from 2.1 to 7.6 
years after transplantation (mean = 4.8 years)13. 
The role of transplantation was also studied in a 
series of 15 children affected by familial choles-
tasis. Eleven children were alive and growing 
well from 1.8 to 6.2 years after transplantation35. 
Alagille's disease is an autosomic disorder char-
acterized by intrahepatic cholestasis and periph-
eral pulmonary artery stenosis. Liver transplanta-
tion is indicated for a subset of these patients 
(usually about 12%) who develop cirrhosis, and 
in the ones with progressive portal fibrosis, 
severe and permanent cholestasis, progressive 
liver dysfunction and growth retardation. In a 
series of 13 patients transplanted for Alagille's 
syndrome, the 7 -year survival rate was 52%. Of 
the 6 mortalities, 4 occurred within 11 days of 
transplant, and the other 2 before the eleventh 
postoperative months. All surviving children 
were growing well and participating in normal 
childhood activities67. 
CONGENITAL ERRORS OF METABOLISM 
Several studies showed in the early 1960's that 
liver allografts retain their metabolic specificity 
after transfer to a new host54, 55It was obvious 
already at that time that a practical implication 
of this fact is that certain liver-based metabolic 
disorders can be cured by liver transplantation. 
The resolution of gout, naturally present in 
Dalmatian dogs, after liver transplantation using 
mongrel canine donors conclusively proved this 
hypothesis58. The fact that the graft maintained 
its phenotype resulted in the cure of congenital 
errors of metabolism in many patients treated by 
liver transplantation for end-stage liver diseas-
es40, 41, 44, 62, 65, 77, 78, 97,105,108,113,130, and anatom-
ically normal livers have also been replaced to 
correct congenital metabolic defects8, 17,20, 146, 
148. As the other side of the coin, there is at least 
one reported case where a coagulation defect of 
the donor was transferred to the recipient by 
liver transplantation29. 
a-I-Antitrypsin Deficiency 
Patients affected by this condition can have pro-
gressive liver injury, eventually resulting in cir-
rhosis and hepatocellular carcinoma34. However, 
the natural history of the disease is quite vari-
able. If cirrhosis occurs, liver transplantation is 
the treatment of choice. After successful trans-
plant, the protease inhibitor status is reversed, 
and depressed serum a-I-antitrypsin levels 
return to normal34,44, 123. 
WIlson's Disease 
This is a genetic disorder of copper metabolism 
characterized by decreased biliary secretion of 
copper and its accumulation mainly in the liver 
and in the brain, and decreased serum cerulo-
plasmin. Recent linkage studies have assigned 
the WIlson's disease locus to chromosome 13, at 
q 14-q216. Its mode of presentation is variable. 
Traditionally, chelation with D-penicillamine is 
the treatment of choice. This has been shown to 
be extremely effective in most patients with 
WIlson's disease, and can frequently interdict the 
need for liver transplantation in patients mani-
festing with chronic hepatitis. Candidates for 
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liver transplantation are those patients present-
ing either with cirrhosis or a picture of fulminant 
liver failure, accompanied by hemolysis and 
renal failure. As in the case of a-I-antitrypsin 
deficiency, liver transplantation cures the under-
lying metabolic defect34, 41. A multicenter study 
published recently showed a I-year survival of 
7go,..{, in 55 patients who underwent liver trans-
plantation in different institutions in the United 
States and Europe107. This study also indicated 
that neurological and psychiatric symptoms 
related to Wilson's disease can improve after 
liver transplantation. 
1Yrosinemia 
Hereditary tyrosinemia is characterized by furn-
maryl hydrolase deficiency, an enzyme respon-
sible for the degradation of metabolic products 
of tyrosine metabolism. Liver dysfunction asso-
ciated with this condition varies from acute 
hepatic fanure to a slowly progressive liver dis-
ease that eventually results in cirrhosis and 
hepatocellular carcinoma34, 36, 146. OLTx is the 
treatment of choice in this situation. 
Hemochromatosis 
Hereditary hemochromatosis is a disorder of 
iron metabolism associated with an abnormal 
gene linked to the A locus of HLA complex on 
chromosome 6. Specifically, hereditary hemo-
chromatosis is associated with the histocompat-
ibility antigens HLA-A3, HLA-BI4, and HLA-
B7133. The syndrome is characterized by inappro-
priate increase in iron absorption and deposi-
tion, with functional impairment of the liver and 
many extrahepatic organs, including pancreas, 
heart, and pituitary. In symptomatic hemochro-
matosis, fibrosis or cirrhosis is present almost 
invariably. If the diagnosis is established early, 
cirrhosis can be prevented by treatment aimed at 
diminishing iron overload (e.g. depletion by phle-
botomy). However, if cirrhosis is present, 10-
years survival is 10% without removal of iron, 
and 32% with phlebotomylO. There is also an 
increased risk of hepatocellular carcinoma95. 
Liver transplantation is indicated when end-stage 
liver disease occurs, and the results justify the 
use of this procedure, both in classical hemo-
chromatosis and in the fulminant pediatric varie-
ty95,116. 
Other Congenital Errors of Metabolism 
At least 16 distinct inborn errors of metabolism 
have been treated by liver transplantation1l6. 
Many other cannot be cured by liver transplanta-
tion and might benefit from allogenic bone mar-
row transplantation92. The guidelines for deci-
sion making in specific metabolic errors became 
increasingly clear in the past decade, allowing 
better care of these patients92, 113. 
TUMORS 
Primary hepatic malignancies were originally 
considered "the indication" for liver transplanta-
tion. Removal of the diseased organ was seen as 
the best treatment for hepatic lesions that could 
not be treated with conventional techniques of 
subtotal liver resection1l4. As a consequence of 
this concept, 11 out of the first 25 patients trans-
planted at the University of ColoradollO had 
hepatocellular carcinoma. However, the results 
with malignant tumors did not fulfill these 
expectations, with high mortality rates due to 
recurrence1l2. The prognosis proved to be differ-
ent in small, incidental tumors. The longest survi-
vor in this group is a patient who underwent 
liver transplantation for biliary atresia on 
January 22, 1970. The removed liver had a 3 cm 
hepatoma, and the patient is still alive and well, 
26 years after the surgery. 
Benign Tumors 
The experience with liver transplatation for 
benign tumors of the liver is stilllirnited, and has 
r 
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yet to be defined. We have previously reported a 
small series of patients transplanted for hepato-
ceUular aderwmatosis andfocal rwdular hyper-
plasia, with 4 out of 5 patients alive from 4.1 to 
9.6 years after liver transplantation. All of these 
patients were activated as transplant candidates 
because of progressive liver failure related to 
multiple lesions that occupied at least 8()O;6 of the 
liver parenchyma, and that were not resectable 
by subtotal hepatectomy71. In a case of hepatic 
lymphangiomatosis, the size of the lesion (the 
liver weighed 16.5 kg), the consequent disability 
(weight loss, pain, pedal edema and dyspnea), 
and the eventual development of significant dete-
rioration of liver function, were the indications 
for transplantation 79. 
Primary Malignant Thmors 
In spite of disappointments due to poor long-
term results, liver malignancies are still treated 
with transplantation in many centers. We believe 
that two points should be made clear when treat-
ing these patients. First, the uncertainty of the 
prognosis must be openly discussed with the 
patient. Secondly, possible metastases should be 
aggressively searched for before candidacy for 
transplantation is established. 
Individuals with hepatic tumors and normal 
liver function can often be treated with liver 
resections. In a study that analyzed the outcome 
of patients with hepatoma, 76 treated by liver 
resection and 105 with liver transplantation, one 
and five year survival rates in the resection 
group were 71% and 33010, respectively, and in the 
transplant group 66% and 36% respectively48. In 
spite of aggressive preoperative evaluation to 
rule out extrahepatic disease, recurrence after 
liver transplantation for malignant tumors is 
invariably high39, 49, 89, 94, 104, 112. Today, we rou-
tinely combine the surgical treatment with adju-
vant chemotherapy which, theoretically, should 
work better when administrated regionally (-
through the hepatic artery branch feeding the 
tumor). The principle underlying this concept is 
that normal parenchyma has a dual blood supply, 
whereas hepatomas receive their blood supply 
mainly through the arterial neo-vasculature16. 
Whether these theoretical benefits will translate 
into reality remains to be seen. 
Certain types of malignant liver tumors have a 
better outcome than others. While Klatskin 
tumors have the poorest long-term survival (no 
survivors at 4.5 years in a previous series of 10 
patients32), epitheloid hemangioendotheliomas 
have a 5-year survival rate of 67%63,72. 
Metastatic Thmors 
Liver transplantation has been used in a very lim-
ited number of tumors metastati.c to the liver46, 
49,64,66,82,89,94. We have recently updated 
(unpublished data) the follow-up of 5 patients 
who underwent liver transplantation for a neuro-
endocrine tumor metastatic to the liver64. Three 
out of these 5 patients died in less than 9 months. 
The other two, long term survivors, also had 
recurrence, with one patient dying 76 months 
after transplantation, and the other still alive 
(June, 1994) 9 years after the transplant.This last 
patient had only a liver transplant plus node dis-
section (possible primary tumor in the pancre-
as). This small experience makes it difficult to 
derive any guidelines. 
RESULTS OF LIVER TRANSPLANTATION 
AT THE PI'ITSBURGH TRANSPLANTATION 
INSTITUTE 
As mentioned before, we analyzed the outcome 
of 1,501 consecutive patients who underwent 
liver transplantation in a 4-year period (January 
1, 1990 - December 31, 1993). Actuarial survival 
curves were estimated using the Kaplan-Meier 
method. Comparisons between groups were 
made using the Breslow test, with a Bonferroni 
adjustment for multiple comparisons. 
The etiology of the liver disease in this popu-
lation is shown in Table 7.49. There were 1,286 
adults and 215 children at the time of their first 
liver transplant (there were 189 retransplants in 
this series), with 934 males and 567 females. The 
mean age was 43.3 ± 19.1 years (range 0.1 to 
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Figure 7.26. Kaplan-Meier actuarial patient and aUo· 
graft survival for 1,501 patients who received 1,690 liver 
allografts at the Pittsburgh Transplantation Institute 
between January 1, 1990, and December 31, 1993. 
76.2), and the mean follow-up was 2.15 years 
(range 0 to 4.5 years). 
The overall actua:rial patient survival rates 
were 81%, 77%, 74%, and 73%, at 1, 2, 3, and 4 
years, respectively (Fig. 7.26). The overall 
actuarial graft survival rates were 72%, 68%, 65%, 
and 64%, at 1, 2, 3, and 4 years, respectively (Fig. 
7.26). Traditionally, patient survival after liver 
transplantation is reported separately for adults 
and children, with the latter usually showing sig-
nificantly better survival. The 215 children « 18 
years) had overall actuarial survivals of 82%,81%, 
80%, and 800Al, at 1, 2, 3 and 4 years, respectively 
(Fig. 7.27), while the 1,286 adults (> 18 years had 
an overall actualial survival of 81%, 77%, 73%, and 
71%, at 1, 2, 3 and 4 years, respectively (Fig. 
7.27). The differrence, however, is not significant 
(p=0.298). 
When the entire patient population is ana-
lyzed according to the diagnosis, after collaps-
ing them into four broad categories (cholestatic, 
alcoholic, parenchymal and metabolic diseases, 
hepatitides), as expected, the cholestatic diseas-
es showed superior results (Fig. 7.28). The actu-
arial survival rates for cholestatic liver diseases 
were 90%, 88%, 87%, and 87%, at 1, 2, 3 and 4 
years, respectively (Fig. 7.28); for the alcoholic 
group, they were 82%, 800Al, 75% and 70%, at 1, 2, 3 
and 4 years, respectively (Fig. 7.28); for the 
parenchymal and metabolic disease group, 
which included all the other parenchymal diseas-
es (excluding tumors), the survival rates were 
78%, 75%, 72%, and 71%, at 1, 2, 3 and 4 years, 
respectively (Fig. 7.28); and for the hepatitides 
they were 79%, 73%, 700Al, and 70%, at 1, 2, 3 and 4 
years, respectively (Fig. 7.28). When compared 
with each other, patients undergoing liver trans-
plantation for cholestatic diseases fared signifi-
cantly better (cholestatic vs. hepatitides: p < 
0.0001; cholestatic vs. alcoholic cirrhosis: p < 
0.0001; cholestatic vs. parenchymal and metabol-
ic diseases: p <0.001). 
The patients who underwent transplantation 
for a malignant primary or secondary liver 
tumor were also analyzed separately, and their 
survival compared with the rest of the patients (a 
number of these patients - see Table 7.49 - had an 
incidental tumor; however, they are not included 
with the "tumor" patients because their progno-
sis had been found in the past to be similar to 
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dren « 18years: 215 patients) and adults (> 18 years: 
1,286 patients) who underwent liver transplantation at 
the Pittsburgh Transplantation Institute between January 
1, 1990 and December 31,1993 (p=0.298). 
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Figure 7.28. Kaplan-Meier actuarial patient survival 
for 1,501 patients who underwent liver transplantation 
at the Pittsburgh Transplantation Institute between 
January 1, 1990, and December 31, 1993. The patients 
were divided into four groups according to the liver 
disease: alcoholic cirrhosis, parenchymal and metabolic 
diseases (excluding tumors), postnecrotic cirrhosis rela-
ted to any type of hepatitis, and cholestatic diseases. The 
latter show a significantly better survival at any given 
interval. 
that of patients with benign disease). The actuar-
ial sUIvival rates for patients undergoing trans-
plantation for cholangiocarcinoma were 70%, 
500;6, 500;6, and 500;6, at 1, 2, 3 and 4 years, respec-
tively (Fig. 7.29: only one patient at risk at 4 
years). The actuarial survival rates for patients 
with a hepatoma known before liver transplanta-
tion were 74%, 65%, 58%, and 58%, at 1, 2, 3 and 4 
years, respectively (Fig. 7.37: only 7 patients at 
risk at 4 years). The actuarial smvival rates for 
patients undergoing OLTx as treatment for a 
tumor metastatic to the liver were 86%, 68%, and 
68% at 1, 2 and 3 years respectively (Fig. 7.29: 
only 2 patients at risk at 3 years). These surpris-
ingly good results might just be related to the 
fact that most of the tumors listed as metastatic 
were neuroendocrine lesions, which have a 
peculiar biological behavior. Finally, actuarial 
smvival rates for those patients with no preoper-
ative evidence of a tumor were 82%, 79%, 77%, 
and 75%, at 1, 2, 3 and 4 years, respectively (Fig. 
7.29: 159 patients at risk at 4 years). As expected, 
patients with no known tumor before transplan-
tation had higher smvival rates. These differenc-
es were significant when comparing their survi-
val rates with those of patients with previously 
known hepatomas (p=0.0006) and cholangiocar-
cinomas (p=0.04). The difference in survival rate 
between patients with no known tumor and met-
astatic disease was not significant (most likely 
the result of the small sample size) . 
Outcome was also analyzed according to the 
United Network for Organ Sharing (UNOS) 
classification. UNOS is the organization mana-
ging organ allocation in the United States. When 
a patient is entered into the system as a trans-
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Figure. 7.29. Kaplan-Meier actuarial survival for 
1,501 patient.s who underwent liver transplantation at 
the Pittsbrugh Transplantation Institute between January 
1, 1990, and December 31, 1993. The patients are divided 
into four groups according to preoperative evidence of a 
liver tumor. The curves show the overall survival rates of: 
[1] patients with no preoperative of a tumor ("no 
tumor"); [2] patients with a tumor metastatic to the liver, 
diagnosed before OLTx; [3] patients with known hepato-
ma before OLTx; and [4)patients with a cholangiocarcino-
ma diagnosed before OLTx. As expected, patients with 
no known tumor before OLTx have higher survival rates. 
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Figure. 7.30. Kaplan-Meier actuarial patient survival 
jor 1,501 patients who underwent liver transplantation 
at the Pittsburgh Transplantation Institute between 
January 1, 1990, and December 31, 1993. The patients are 
divided into 3 groups, according to the United Network 
for Organ Sharing (UNOS) classification. UNOS is the 
organization managing organ allocation in the Untied 
States. UNOS 2 = stable patient who can wait for the 
transplant at home; UNOS 3 = unstable patient who 
needs to wait for the transplant in the hospital; UNOS 4 = 
critically ill patient who needs life support. 
plant candidate he is given a score according to 
the severity to which the disease has progressed. 
UNOS 2 indicates that the patient is stable and 
can wait for the transplantation at home. UNOS 
3 means that the patient is medically unstable 
and needs continuous hospitalization. UN OS 4 
indicates that the patient's condition has deteri-
orated to the point at which life-support systems 
are required. 
Actuarial survival rates for UNOS 2 patients 
were 85%, 82%, 79%, and 79%, at 1, 2, 3 and 4 
years, respectively. For UNOS 3 patients they 
were: 86%, 82%, 78%, and 78%, at 1, 2, 3 and 4 
years, respectively. Finally, for UNOS 4 patients 
they were 75%, 72%, 690;6, and 67%, at 1, 2, 3 and 4 
years, respectively (Figure 7.30). There was no 
statistical difference between UNOS 2 and UNOS 
3 patients. However, both UNOS 2 and UNOS 3 
patients had significantly better outcome than 
UNOS 4 patients (UNOS 2 vs. UNOS 4: p=0.OO5; 
UNOS 3 vs. UNOS 4: p < 0.0001) . 
SPECIAL CONSIDERATIONS 
There are a few other issues regarding candidacy 
to liver transplantation that should be discussed. 
It is a policy in most centers in Europe, and in 
many in the United States, to limit candidacy 
based on the age of the recipient. A simple upper 
age limit is not used at our Institute, since it has 
been our experience that older patients have 5-
vears survival rates that are similar to that of 
younger groups128, 131. 
Thrombosis of the portal vein, and/or the mes-
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Figure 7.31. Kaplan-Meier actuarial pat'ient survival 
jor ortiwtopic liver transplantation in the azothioprine 
and cyclosporine eras, in the single consecutive 
Denver-Pittsburgh series 0963-1988).One hundred and 
seventy patients were transplanted between MarchI, 
1963, and February 3, 1980, and were treated with 
azothioprine, while 1,672 patients were transplanted 
between March 9, 1980, and December 30, 1988, and 
were treated with cyclosporine. The numbers on the cur-
ves indicate the population at risk (From: Marino, I.R., 
Doyle, H.R.: Conventional immunosuppressive drugs. In: 
Immunosuppressive Drugs. Developments in Anti-
Rejection Therapy A.w.Thompson and Th.E.Starzl, eds.], 
pp. 1-14. Edward Arnold, London 1994, used by permis-
sion). 
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enteric and splenic vein were in the past consid-
ered as contraindication to liver transplantation. 
These problems were almost completely elimi-
nated by the use of cadaveric vein grafts 109, 121, 
132,140. The vein graft is anastomosed end-to-side 
to a patent segment of the superior mesenteric 
vein, and then brought into the subhepatic area 
where it is used to revascularize the portal vein 
of the allograft. Also, previous abdomirwl sur-
gery can seriously complicate the transplant 
operation, and it was once considered a contra-
indication to liver transplantation by many liver 
transplant centers. The greatest concerns were 
raised by previous operations on the porta hepa-
tis and, in fact, the majority of technical compli-
cations involving the portal vein have been 
described in transplants performed after shunt 
surgeries61. Nowadays, these technical issues are 
not considered an obstacle at any major trans-
plant center. Imaging techniques provide enor-
mous help in defining the surgical strategy in 
advance. 
The last issue we would like to address is related 
to the question of candidacy to liver transplanta-
tion for the patients carrying antibodies to the 
human immunodeficiency virus (HIV). After 
the screening enzyme immunoassay for detect-
ing HIV antibodies became available in March 
1985, a number of positive kidney, heart, and 
liver recipients were quickly reported59, 97. 
However, the extent of the problem was clearly 
defined only after a large study was completed at 
the University of Pittsburgh. The stored sera of 
1,043 transplanted patients were tested for HIV 
antibodies, and 1.7% were found to be positive28. 
Liver transplant patients showed a higher risk, 
with an incidence of 2.6%. One third of these 
liver patients were positive before the transplant. 
Fifteen liver patients were then followed, along 
with 5 heart and 5 kidney transplant recip-
ients139. The survival of the 15 liver HIV + 
patients was compared to a group of 1,303 HIV-
patients who underwent liver transplantation 
during the same years. Kaplan-Meier actuarial 
survival was identical at one year. Survival was 
shorter for the HIV+ group at 2 or more years. 
Given the actual shortage in donor livers, it 
therefore seems justified that HIV+ patients will 
not be considered as transplant candidates at 
many institutions, both in the United States and 
in Europe. 
CONCLUSIONS 
Indications for liver transplantation have been 
expanded substantially in the last 30 years. Many 
factors that were previously considered as con-
traindications, like an upper age . limit of 50, alco-
holic cirrhosis, multiple abdominal operations, 
and HIV antibody carrier status are not any long-
er preventing candidacy for liver transplantation. 
In patients suffering from an end-stage liver dis-
ease that is known not to recur in the transplant-
ed allograft candidacy is no longer debatable. On 
the other hand, it is controversial what role 
should liver transplantation have in the treat-
ment of diseases with high recurrence rates, 
such as hepatitis B and most malignant tumors. 
However, liver transplantation should not be 
arbitrarily refused to any of these patient groups. 
Patients at high risk for recurrent disease should 
be evaluated and entered into new protocols that 
may, eventually, improve their prognosis. Prime 
examples are the preoperative treatment of can-
didates carrying a primary hepatic malignancy 
with intra-arterial and/or systemic chemothera-
py., and the use of novel antiviral agents for pre-
vention of treatment of recurrent viral hepatitis 
B. 
In June 1983, the Consensus Development 
Conference of the National Institutes of Health 
concluded that: "liver transplantation is a thera-
peutic modality for end-stage liver disease that 
deserves broader application". This sentence had 
a tremendous impact on the expansion of liver 
transplantation as a routine surgical service. 
Long-term survival ( > 10 years), which was 
uncommon until the beginning of the 1980's, 
increased tremendously with the introduction of 
new immunosuppressive agents (Fig. 7.31), and 
technical refinements of the procedure1l9. 
Nevertheless, liver transplantation is still viewed 
as a high-technology procedure that society can 
do without. This view is surprisingly common in 
the United States and Europe. In 1991, 75 
Directors of the British health system were inter-
viewed about the priority of 12 given health care 
treatments. Liver transplantation ranked 
eleventh, and only the treatment for advanced 
lung cancer ranked lower. The treatment of AIDS 
and dialysis ranked significantly higher (seventh 
and forth, respectively)22. We believe such 
notions are wrong, and not supported by the cur-
2120 OPERATIONS: INDICATIONS, COMPLICATIONS AND RESULTS 
rent long-term results. Liver transplantation is 
certainly a safe procedure and the only curative 
treatment for many people suffering from end-
stage liver disease. The cost of the procedure 
and the organ shortage are the two main prob-
lems that should be addressed in the coming 
years. 
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